6533b834fe1ef96bd129d635
RESEARCH PRODUCT
Cerebrovascular involvement in fabry disease: current status of knowledge.
Andreas FellgiebelThanh G. PhanPaul A. CarusoMax J. HilzAlessandro P. BurlinaRenzo ManaraJuan PoliteiEdwin H. KolodnyKatherine B. Simssubject
Pathologymedicine.medical_specialtyCell typeGlobotriaosylceramideIschemiaInflammationMuscle hypertrophychemistry.chemical_compoundFibrosisLeukoencephalopathiesInternal medicinemedicineHumansAdvanced and Specialized Nursingbusiness.industrymedicine.diseaseFabry diseasePathophysiologyStrokeCerebrovascular DisordersEndocrinologychemistryFabry DiseaseNeurology (clinical)medicine.symptomCardiology and Cardiovascular Medicinebusinessdescription
Fabry disease (FD) is a rare and highly debilitating lysosomal storage disorder that results from a total lack of, or deficiency in, the enzyme α-galactosidase A (α-Gal A) because of mutations in the GLA gene.1 FD is inherited as an X-linked trait; many of the male patients develop a classic severe phenotype with early onset of symptoms, whereas heterozygous females exhibit phenotypes ranging from asymptomatic to major involvement of vital organs.2 Most families inherit private mutations; to date, >600 mutations have been identified and are listed in the online FD database (Fabry-database.org).3 The deficiency in α-Gal A causes the accumulation of globotriaosylceramide (GL-3; also abbreviated Gb3) in various cellular compartments, particularly lysosomes, causing structural damage and cellular dysfunction, as well as triggering secondary, tissue-level responses, such as inflammation, ischemia, hypertrophy, and the development of fibrosis resulting in progressive organ dysfunction.4 Deacylated globotriaosylceramide (lyso- globotriaosylceramide [lyso-GL-3]) has also been shown to be present in increased concentrations in the plasma of patients with FD. It has been suggested that lyso-GL-3 promotes GL-3 accumulation, induces proliferation of smooth muscle cells in vitro, and may have deleterious effects on the intima and media of small arterioles.5 Many cell types are involved in FD pathology, including vascular cells (endothelial and smooth muscle cells), cardiac cells (cardiomyocytes and valvular cells), a variety of renal cells (tubular and glomerular cells, and podocytes), and nerve cells.2 The underlying pathophysiological mechanisms of FD are complex and incompletely understood.6 Early pathophysiological changes are thought to predominantly involve the microvasculature.7 As age increases, arterial remodeling and intima-media thickening in medium-to-large caliber vessels occur.2 The first clinical symptoms of FD occur in childhood (eg, neuropathic pain, hypohidrosis, and gastrointestinal problems)8 and are primarily because of autonomic neuropathy.9 As the disease …
year | journal | country | edition | language |
---|---|---|---|---|
2014-12-11 |